- CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc.
Website
Offer Price
Offer Size
3-Year Outlook
Volatility
1st Day Turnover
$15.00
18,800,000
Positive
High
5.91%
Offering Team
Deal Managers
- J P Morgan Chase
- Jefferies
- Truist Securities
Lawyers
- Latham & Watkins LLP
Auditors
- Deloitte & Touche LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
We are a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients. Our programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. A CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. We believe the limitations of approved thera More
Deal Tracker
Investors
Filing
09 Nov, 2023Offer
10 Nov, 2023Look Ahead
Lock Up Expiry
10 May, 2024Earning
Nov 1, 2018IPO Terms
Offer Price | $15.00 |
Offer Size | 18M |